AbstractBySubCategory

Multidisciplinary Treatment

Cancers of the Colon, Rectum, and Anus

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). Scott Kopetz

520

The International Watch & Wait database (IWWD) for rectal cancer: An update. Maxime van der Valk

521

Effect of sex on treatment outcomes in rectal cancer patients after neoadjuvant radiotherapy or chemoradiation: A combined analysis of Polish-1 and Polish-2 studies. Lucjan Wyrwicz

656

Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC). Herbert Hurwitz

657

CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209). Hans-Joachim Schmoll

658

Associations of physical activity with survival and progression in metastatic colorectal cancer: Results from CALGB 80405 (Alliance). Brendan John Guercio

659

Nintedanib (N) plus best supportive care (BSC) versus placebo (P) plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Subanalysis of the phase III LUME-colon 1 study in pts by prior regorafenib (R) treatment. Heinz-Josef Lenz

660

Randomized phase II study of panitumumab (Pmab) + irinotecan (CPT-11) versus cetuximab (Cmab) + CPT-11 in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) after fluoropyrimidine (FU), CPT-11, and oxaliplatin (L-OHP) failure: WJOG6510G. Naotoshi Sugimoto

661

Total neoadjuvant therapy for locally advanced rectal cancer. Andrea Cercek

662

Efficacy/safety analysis of a phase 2 study of ruxolitinib (Rux) + regorafenib (Re) in patients (pts) with relapsed/refractory (r/r) metastatic colorectal cancer (mCRC). David R. Fogelman

663

Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer. John M. Creasy

664

The behavior of colorectal liver metastases in the time frame between the end of preoperative chemotherapy and liver resection: A new selection criterion for technically resectable patients. Luca Vigano

665

Unresectable colorectal cancer liver metastases treated with radioembolization: Updated survival analysis of the MORE study. Andrew S. Kennedy

666

Baseline creatinine clearance as an indicator of severe adverse events associated with oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer: Safety analysis of the phase III Japanese ACHIEVE trial. Masato Nakamura

667

Exploratory analysis of left- versus right-sided colorectal carcinoma in RAISE: A randomized, double-blind, phase 3 trial of ramucirumab (RAM) + FOLFIRI versus placebo (PBO) + FOLFIRI. David Craig Portnoy

668

Association of delayed commencement of adjuvant chemotherapy (AC) with inferior survival in colon cancer patients with stage II and III diseases: A national population-based cohort study. Ik Yong Kim

669

The prognostic impact of surgical complications after combined modality treatment of rectal cancer: Long-term results of the CAO/ARO/AIO-94 trial. Thilo Sprenger

670

Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study. Heinz-Josef Lenz

671

Oral adjuvant chemotherapy using uracil-tegafur (UFT) with leucovorin (LV) after resection of colorectal cancer liver metastases: Long-term survival results of the phase III UFT/LV study. Kiyoshi Hasegawa

672

Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). Howard S. Hochster

673

Primary tumor location and survival in general population with metastatic colorectal cancer (mCRC). Shahid Ahmed

674

Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. Mohamed E. Salem

675

Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway. Herbert Hurwitz

676

BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer. Tim Larson

677

Neoadjuvant chemoradiation for locally advanced rectal cancer with fluoropyrimidine alone or intensified with oxaliplatin: A systematic review and meta-analysis. Ashlie Nadler

678

Longitudinal trajectory of cancer survivorship in patients with recurrent rectal cancer: Anatomy of recurrence in relation to quality of life and pain. Tarik Sammour

679

Comparison of 5-FU versus capecitabine in combination with mitomycin or cisplatin in the treatment of anal cancer. Irene S. Yu

680

A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT). Masato Nakamura

681

Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease. Belinda Lee

682

Impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) ± cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial. Shukui Qin

683

Evolution in multimodality management of locally advanced rectal cancer. Campbell SD Roxburgh

684

Phase I study of neoadjuvant 5-fluorouracil (5FU) chemoradiation (CRT) and trametinib in patients with locally advanced rectal cancers (LARC). Christina Sing-Ying Wu

685

Factors predictive of receiving neoadjuvant versus adjuvant chemoradiotherapy in locally advanced rectal cancer and the impact on overall survival. Alex Richard Coffman

686

Application of the ASCO framework for assessing value in metastatic colorectal cancer clinical trials. Doreen Anuli Ezeife

687

Clinical outcomes of positive resection margins after endoscopic resection of early colorectal cancer. Jin-Oh Kim

688

The relationship between tumor location, tumor microenvironment, systemic inflammation, and cancer-specific survival in patients undergoing surgery for colon cancer. Meera Patel

689

Does the addition of biologic agents to chemotherapy in patients with unresectable colorectal cancer metastases result in a higher proportion of patients undergoing resection? A systematic review and meta-analysis. Jessica Bogach

690

Racial and gender disparities in therapy and outcomes of squamous cell cancer of the anus. Arjun Gupta

691

Cost of colon cancer care: Results of nationwide inpatient sample (NIS) data. Pranshu Bansal

692

Effect of neoadjuvant IMRT for locally advanced rectal cancer on toxicity and pathologic response. John David

693

Impact of primary tumor sidedness on survival after resection of colorectal liver metastases (CRLM). Richard M. Lee-Ying

694

Survivorship after lower gastrointestinal cancer: Patient reported outcomes and planning for care. Melissa Frick

695

Institutional variation in the thoroughness of pathologic assessment and pathologic complete response rates for locally advanced rectal cancers treated with neoadjuvant chemoradiation. Oliver S Chow

696

Predictive value of PET/CT for pathological complete response and survival in patients with locally advanced rectal cancer. Eric C Sorenson

697

QTWIST analysis in the RECOURSE trial. Josep Tabernero

698

Cetuximab (Cet) clearance and survival in patients (pts) with metastatic colorectal cancer (mCRC). Di Maria Jiang

699

Safety and effectiveness of regorafenib (REG) in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: An interim analysis (IA) from the prospective, observational CORRELATE study. Michel Ducreux

700

Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer. Amitesh Chandra Roy

701

Impact of country-specific health economic guidelines on cost-effectiveness (CE) estimates: An illustrative study of the CE of cetuximab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC). Gerard Harty

702

Treatment outcome and recovery from peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer (JFMC41-1001-C2: JOIN Trial). Dai Manaka

703

Incidence and outcomes of hospitalized patients with gastrointestinal malignancies and Clostridium difficile infection: A nationwide analysis. Arjun Gupta

704

Oncopre: A new chemotherapy benefit prediction algorithm to assist treatment decision making. Dimas Yusuf

705

Phase 1 trial of OCV-C02, a peptide vaccine for metastatic colorectal cancer patients refractory to all standard chemotherapies. Satoru Iwasa

706

A phase II study of ziv-aflibercept (Z) + FOLFIRI in Japanese patients (pts) with metastatic colorectal cancer (mCRC). Taroh Satoh

707

Preoperative chemoradiotherapy for advanced lower rectal cancer using SOX+Bev regimen. Jun Higashijima

708

Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT). Francesco Sclafani

709

Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer. Jonathan M. Loree

710

Primary tumor location as a prognostic and predictive factor in metastatic colorectal cancer (mCRC) treated with chemotherapy plus cetuximab: A retrospective analysis. Tamotsu Sagawa

711

Minimally invasive surgery to improve time to chemotherapy in colon cancer: Compliance to the American College of Surgeons Commission on Cancer quality metrics. Sinziana Dumitra

712

Baseline absolute neutrophil counts (ANC) and survival in second-line metastatic colorectal cancer (mCRC) patients (pts). Axel Grothey

713

Response to pembrolizumab in patients with mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). Alexis Diane Leal

714

Minimally invasive complete mesocolic excision and central vascular ligation for right colon cancer: Defining the radicality of central lymphadenectomy. Tarik Sammour

715

Association of adjuvant chemotherapy with improved overall survival for patients with locally advanced rectal cancer (LARC) who achieve a pathologic complete response (pCR) to neoadjuvant chemoradiation (nCRT). Danish Shahab

716

Effect of adjuvant chemotherapy following pathologic complete response on long-term survival in rectal cancer: A propensity score matched analysis. Ali Mokdad

717

Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer. Joel Lange

718

Impact of time to surgery in locally advanced rectal cancer patients. Madiha Naseem

719

Effect of number of prior lines versus prior regimens in pts receiving trifluridine/tipiracil (TAS-102). Eric Van Cutsem

720

Safety and efficacy of regorafenib post-marketing surveillance (PMS) in Japanese patients with metastatic colorectal cancer (mCRC). Yoshito Komatsu

721

A phase II study of panitumumab with FOLFOX or FOLFIRI as first-line chemotherapy for KRAS-wild type metastatic colorectal cancer: The PaFF-J study. Eiji Shinozaki

722

Nationwide incidence, treatment, and outcomes of patients 80 years and older with rectal adenocarcinomas: Analysis of 5,076 patients. Richard John Cassidy

723

Current alignment between the practice patterns of gastrointestinal (GI) cancer clinical investigators (CI) and general medical oncologists (MO) in the treatment of metastatic GI cancers. Neil Love

724

Representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Jennifer Tseng

725

Utilization of primary chemoradiotherapy for anal squamous cell carcinoma in the elderly: An analysis of the NCDB. Benjamin Mitchell Motz

726

Examining progression-free survival in first- and second-line treatment for BRAF-mutant metastatic colorectal cancer (CRC). Belinda Lee

728

Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): Validation in the phase III WJOG4407G trial. Kentaro Sakamaki

729

Ten-year survival data following resection of locally recurrent rectal cancer (LRRC). David Patrick Cyr

730

Retrospective analysis of the effects of systemic chemotherapy to the ovarian metastases from colorectal cancer. Katsutoshi Sekine

731

Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis. Yanqiao Zhang

732

Utilization of minimally invasive versus open colectomy for colon cancer and perioperative/short-term oncologic outcomes: Are we there yet? Jillian K. Smith

733

Comparative analysis of survival in colon cancer undergoing sentinel lymph node mapping versus conventional surgery based on number of positive lymph nodes. Sabarina Ramanathan

734

Efficacy and safety of regorafenib compared to TAS-102 for metastatic colorectal cancer: A systematic review and network meta-analysis. Ana Beatriz Kinupe Abrahao

735

Oncologic outcome and morbidity for elderly rectal cancer patients compared to younger patients after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study. Soo Yoon Sung

736

Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial. Antoine Adenis

737

Utilization of systemic therapy options in the routine treatment of metastatic colorectal cancer. Rachel Lee Delahunty

738

Demographic and clinical characteristics of patients with metastatic colorectal cancer (mCRC) associated with RAS testing from 129 million covered lives. Bruce A. Bach

739

The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients’ characteristics and safety analysis. John Souglakos

740

Prognostic impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) at the salvage lines. Tomoyuki Nagaoka

741

Overall survival of elderly metastatic colorectal cancer patients treated in second and third line by tumor site. Patricia Luhn

742

Fast track multidiscipline treatment versus conventional treatment for colorectal cancer: The results of a prospective randomized controlled study (FTMDT trial). Ke-Feng Ding

743

Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status. Katsuyuki Murai

744

Phase I/II trial of dose reduced capecitabine in elderly or frail patients with untreated advanced colorectal cancer. Daniel Adam Breadner

745

A prospective, randomized study of low molecular weight as supplemental therapy in metastatic colorectal cancer patients treated with FOLFIRI regimen and target agents. Hsiang-Lin Tsai

746

Hepatic artery therapies for unresectable colorectal liver metastases: Pooled survival analysis of 968 patients from TACE, yttrium-90, and HAI studies. Vitor Moutinho

747

Role of cetuximab in conversion therapy in advanced KRAS WT colorectal cancer with liver limited disease: A systematic review and meta-analysis. Michelle McMullen

748

Effect of multidisciplinary tumor conference on clinical management of rectal cancer. Georgios Karagkounis

749

Treatment sequencing and outcomes in synchronous metastatic rectal cancer. Madeleine Cornelia Strach

750

Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP). Fernando Rivera

751

Nonagenarian patients with metastatic colorectal cancer: Results from the South Australian metastatic colorectal cancer registry. Timothy Jay Price

752

An international patient-centered outcome measurement set for colorectal cancer. Harvey J. Mamon

753

Bevacizumab and its impact on survival for patients receiving subsequent ANTI-EGFR therapy: Results from the South Australian metastatic colorectal cancer registry. Timothy Jay Price

754

Reinduction of oxaliplatin-based chemotherapy after exposure to oxaliplatin in adjuvant setting for colorectal cancer. Seung-Hoon Beom

755

High-dose neoadjuvant intensity modulated radiotherapy/chemotherapy for distal rectal cancer followed by rectal sparing TEM. Albert S. DeNittis

756

Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database. Alexis Diane Leal

757

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. Shaan Dudani

758

A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer. Patrick McKay Boland

759

Cetuximab (CTX) in first-line treatment of elderly patients with metastatic colorectal cancer (mCRC), KRAS wild type: French multicentre prospective community-based registry and results. Laurent Mineur

760

Chemotherapy for metastatic colon cancer: Effect on survival when the dose is reduced due to side effects. Stefan Munker

761

An update on rectal cancer evaluation by magnetic resonance imaging in neoadjuvant therapy decision making: Retrospective case review. Alejandro Recio Boiles

762

Comparison of survival for left-sided KRASwt mCRC patients treated with anti-EGFR based therapy as compared to right-sided mCRC. Lubos B. Petruzelka

763

Patient reported distress is predictive of survival in patients with gastrointestinal tumors. Dale Alan Whitaker

764

Effect of extended postoperative recovery on long-term oncological outcomes. Elizabeth Poli

765

Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database. Tomasz Burzykowski

766

Immunotherapy using activated T cells with chemotherapy for metastatic colorectal cancer. Yoichiro Yoshida

767

Tumor sidedness, adjuvant chemotherapy (AC), and other factors affecting survival in patients with stage II colon cancer (CC-II). Shiva Kumar Reddy Mukkamalla

768

Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectal cancer (mCRC) in daily practice in Germany: Interim results of the prospective multicentre noninterventional RECORA study. Holger Schulz

769

A phase I/II study for panitumumab combined with TAS-102 in patients with RAS wild-type metastatic colorectal cancer (APOLLON study): Phase I results. Takeshi Kato

770

Left versus right: Does location matter for refractory metastatic colorectal cancer (mCRC) patients in phase I clinical trials? Sukeshi R. Patel

771

Does primary site of colorectal cancer become a prognostic factor of patients undergoing curative resection of liver metastases? Rika Kizawa

772

Impact of RAS testing on treatment duration among patients with metastatic colorectal cancer (mCRC). Bruce A. Bach

773

Analysis of clinical and research implications of expanding next-generation sequencing (NGS) libraries in the treatment options of gastrointestinal cancers in a large cancer center. Miguel Gonzalez Velez

774

Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer. Atsushi Ohtsu

775

Intermittent maintenance treatment with bevacizumab in patients with metastatic colorectal cancer: A single centre experience. Eleonora Cerchiaro

776

Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis. Gong Chen

777

Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer—HGCSG1401. Yumiko Ota

778

The risk factors for vomiting and nausea in patients with oxaliplatin-based chemotherapy: Subgroup analysis of SENRI trial. Junichi Nishimura

779

Treatment strategy for colorectal liver metastases: Clinical impact of FOLFOXIRI regimen for unresectable cases. Yuji Morine

780

Phase II trial of capecitabine +/- erlotinib in advanced colorectal cancer, with retrospective KRAS and primary tumor site analysis. Daniel Adam Breadner

781

Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials. Daisuke Sakai

782

Self-reported adherence to regorafenib for metastatic colorectal cancer: A retrospective cohort study. Kazuyoshi Kawakami

783

Adjuvant treatment in extreme elderly patients with colorectal cancer. Marta Llopis Cuquerella

784

Impact of clinical and molecular features on risk of recurrence following curative intent resection of metastases in metastatic colorectal cancer. Matthew E. Burge

785

Prognostic impact of tumor (T) and lymph node (N) status in metastatic colon cancer (MCC): A validation study using the National Cancer Database (NCDB). Shiva Kumar Reddy Mukkamalla

786

Impact of robotic-assisted approach on lymphadenectomy for colorectal cancer. Reza Gamagami

787

Time to grade ≥3 adverse events in pts receiving trifluridine/tipiracil (TAS-102). Eric Van Cutsem

788

ECOG performance status as a predictor of adjuvant chemotherapy (AC) toxicities in stage III colorectal cancer (CRC) patients. Akie Watanabe

789

Rectal adenocarcinoma: Outcomes of adjuvant chemotherapy after neoajuvant chemoradiotherapy in a retrospective cohort. Vanessa Pachón Olmos

790

Comorbidities limiting recruitment of colorectal cancer (CRC) patients in early-phase trials. Narjust Duma

791

Pembroliuzmab in gastrointestinal (GI) malignancies with defective DNA mismatch repair (dMMR): A single institution experience. Courtney C Cavalieri

792

Vitamin D levels among patients with colorectal cancer (CRC) from the San Francisco Bay area. Marissa Barbara Savoie

793

A retrospective analysis on the impact of preoperative neutrophil to lymphocyte ratio in stage II colon cancer. Deepna Jaiswal

794

The efficacy and safety of CapeOX plus bevacizumab therapy with a planned oxaliplatin stop-and-go strategy in patients with metastatic colorectal cancer: A multi-center, single-arm, phase II study (CCOG-0902 study). Yuuki Sunakawa

795

Protective effect of ursodeoxycholic acid against chemotherapy-induced mucositis. Seung Han Kim

796

Retrospective review of outcomes in patients (pts) with synchronous metastatic rectal cancer (mRC) receiving initial non-surgical management. Ella Torti

797

Evaluation and response of mucin pools in primary rectal cancer tissue during chemoradiotherapy (CRT). Hiroshi Miyakita

798

Exploratory evaluation of pharmacodynamic biomarkers and pharmacokinetics (PK) of ziv-aflibercept (Z) + FOLFIRI in a phase II study of Japanese patients (pts) with metastatic colorectal cancer (mCRC). Takayuki Yoshino

799

Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months. Kaori Hayashi

800

Response rate and survival for patients with metastatic colorectal cancer from right-sided versus left-sided tumors, treated with first-line triplet chemotherapy with bevacizumab. Shouki Bazarbashi

801

Clinical trials versus clinical practice in colorectal cancer: Equivalent populations? Alejandra Magdaleno Cremades

802

Genomic-directed therapy of gastrointestinal cancers by comprehensive genomic profile (CGP): Clinical and genomic characteristics at the John Theurer Cancer Center (JTCC). Miguel Gonzalez Velez

803

Relations of changes in serum carcinoembryonic antigen (CEA) levels before and after chemoradiotherapy (CRT) and after surgery to histological response and outcomes in patients with locally advanced rectal cancer (LARC). Gota Saito

804

The utilization of multidiciplinary tumor boards (MDT) in clinical routine: Results of a health care research study focusing on patients with metastatic colorectal cancer. Kia Homayounfar

805

Maintenance treatment with capecitabine plus cetuximab after first-line standard fluorouracil-based chemotherapy plus cetuximab for patients with RAS wild-type advanced colorectal cancer. Xianglin Yuan

806

North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003). Toshiaki Shichinohe

807

Consolidation chemotherapy for locally advanced mid- or low rectal cancer after neoadjuvant concurrent chemoradiotherapy: A multicenter, randomized controlled trial (KONCLUDE). Chang Woo Kim

TPS813

Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform. Thomas J. George

TPS814

KEYNOTE-177: Randomized phase III study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair-deficient or microsatellite instability-high metastatic colorectal carcinoma. Luis A. Diaz

TPS815

Totally neoadjuvant chemoradiation therapy with mFOLFOX6 in locally advanced rectal cancer: A single arm phase II study (FOTAC). Jianwei Zhang

TPS816

A randomized phase II study to investigate the deepness of response (DpR) of FOLFOXIRI plus cetuximab (Erbitux) versus FOLFOXIRI plus bevacizumab as the first-line therapy in metastatic colorectal cancer (mCRC) patients with RAS wild-type tumors: DEEPER. Akihito Tsuji

TPS818

An open-label, randomized, controlled clinical trial to explore the curative effects between the treatment of capecitabine and andrographolide and the single capecitabine in the patients with pathological and/or histologic diagnosed unresectable, advanced, recurrent, and metastatic colorectal cancer. Yongqian Shu

TPS819

Steroid-free regimen with aprepitant in preventing chemotherapy-induced nausea and vomiting in patients with colorectal cancer receiving FOLFOX chemotherapy: A randomized phase III trial. Wenjing Wang

TPS820